Keyword: Akcea Therapeutics
For $250 million up front, Akcea is licensing an antisense therapy to Pfizer, to be developed for “certain cardiovascular and metabolic diseases.”
A week after Sarah Boyce exited Akcea, she's at the helm of Avidity Biosciences, a company aiming to take antibody-drug conjugates to the next level.
GSK CEO Walmsley joins Microsoft board; Tivicay co-creator Johns to head HemoShear R&D; Ionis' CBO McDevitt to helm Akcea on an interim basis.
Akcea CEO Paula Soteropoulos, President Sarah Boyce and Chief Operating Officer Jeff Goldberg are bidding the company adieu.
The decision sets Novartis up to test the RNA-targeting drug in a phase 3 cardiovascular outcomes trial.
Akcea and Ionis' self-administered Tegsedi is more convenient than Alnylam's Onpattro, but it comes with a boxed warning.
Intellia Therapeutics is developing a CRISPR-based treatment to edit the mutation that causes transthyretin amyloidosis.
Akcea has its first FDA approval for hATTR therapy Tegsedi but will be burdened with a black box warning as it chases rival Alnylam.
Akcea reported topline data showing its hyperlipoproteinemia drug lowered lipoprotein(a) levels in a phase 2 study in patients with cardiovascular disease.
Ex-Gilead CMO Andrew Cheng to lead Akero; Sanofi trades executives with Bayer in restructuring; and Crescendo names ex-Roche leader as CMO.